No More Sales-NpFlamma® HGC 648

Product#: Inactivated-PNC1201
$99,999.00

Packing Unit

  • 10 tests
  • 50 tests
  • 250 tests
Availability:
Ships in 24 hours

You are currently tracked by Google's cookies
based on your browsing history record.
We apologize for any inconvenience.
Please, Feel free to Explore or Search
the Diagnocine website for more information.
Let me know if you need further adjustments!

NpFlamma® HGC 648

Cat. No. List below

Description
NpFlamma® HGC 648 is a red dye-incorporated chitosan based amphiphilic nanoparticle that enables to selectively detect tumor cells. Flamma® Fluor dyes display strong absorption, high fluorescence quantum yield and high photostability, and they maintain good fluorescence activity and stability after conjugated to biomolecules. The maxima of Ex/Em values are at 648/663 nm. NpFlamma® HGC 648 enables to observe non-invasive images of cancer metastases and to contrast blood vessel. We offer NpFlamma® HGC 648 as an effective fluorescence agent for in vivo imaging of angiography and tumor progression. 
 
Specifications
  • Fluorophore: Flamma® Fluors 648
  • Application: In vivo imaging
  • Particle size: ~250 nm
  • Excitation/Emission Max.(nm): 648/663 
  • Appearance: Blue Solid  
  • Storage conditions: 4 ℃, protect from light

Table 1.  NpFlamma® HGC series list
 
Quick link (Cat.#) Series Ex * (nm) Em* (nm) Common
filter set
Excitation
source
PNC1201 NpFlamma® HGC 648 648 675 Cy 5 594, 633 nm
PNC1401 NpFlamma® HGC 675 675 698 Cy 5.5 633, 680 nm
PNC1301 NpFlamma® HGC 749 750 782 Cy 7 680 nm
PNC1601 NpFlamma® HGC 774 777 802 Cy 7.5 785 nm
PNC1501 NpFlamma® HGC ICG 785 821 Cy 7.5 785 nm


Overview

NpFlamma® HGC series is a fluorescent dye incorporated chitosan based amphiphilic nanoparticles that enables to selectively detect tumor cells. Chitosan nanoparticles can selectively accumulate in cancer tissues due to high permeability for new blood vessels in cancer tissues. Chitosan particles display low toxicity along with absence of noticeable side effect in vivo, yet they exhibit a long half-life, high stability and aqueous solubility. Thus, NpFlamma® HGC series is an ideal fluorescence agent for in vivo imaging of angiography and tumor progression. The hydrophobic nature of NpFlamma® HGC series can embed hydrophobic materials, thus they can be utilized as a selective carrier for hydrophobic cancer drugs such as doxorubicin and paclitaxel, etc.
 

NpFlamma HGC_Fig1.png

Figure 1. In vivo tumor imaging of NpFlamma® HGC series
 
NpFlamma HGC_Fig2.png NpFlamma HGC_Fig3.png
Figure 2. In vivo imaging of five NpFlamma® HGC series over seven days
Fluorescence from cancer cell continued after 7 days injection, but fluorescence from other organs disappeared.
Figure 3. Comparison of ex-vivo imaging of NpFlamma® HGC and another imaging agent
NpFlamma® HGC series displays higher tumor cell accumulation than that of AngioSense


In vivo Imaging Protocol

General
- Prepare the fluorescent probe solution by adding DW or PBS to the NpFlamma® HGC series powder and vortex the mixture (1does = 120 μg per 100 μL)
- Since fluorescent substances are unstable under light, they should be stored in the dark.
- Mouse fur may cause scattering or absorption of excitation of light during optical imaging process. Use nude mouse or remove the mouse fur in advance.
- It is recommended to use 31 G syringe needle.
- Prepare 5 week-old male Balb/c-nude mouse.

Typical procedure for mouse model tumor imaging with NpFlamma® HGC
- Inject SCC7 cell line (1x106 per 0.1 mL) into subcutaneous of Balb/c-nude mouse.
- When the volume of tumor cell reaches to 60~80 mm3, take the zero time image of each subject.
- Inject NpFlamma® HGC series (120 μg per 100 μL) intravenously to mouse.
- The optimal interval for fluorescence imaging is 1 h, 3 h, 6 h, 9 h, and 24 h after injection.
- After take the 24 h imaging, extract major organs (liver, lung, spleen, kidney, heart) and tumor cell, and perform the ex-vivo imaging process.

Citation & Reference


1.  New generation of multifunctional nanoparticles for cancer imaging and therapy (Kyeongsoon Park, Seulki Lee, Eunah Kang, Kwangmeyung Kim, Kuiwon Choi, Ick Chan Kwon, Advanced Functional Materials, 2009, Volume 19, Issue 10, Pages 1553–1566)

2.  Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring (Kwangmeyung Kim, Jong Ho Kim, Hyungkyu Park, Yoo-Shin Kim, Kyeongsoon Park, Heayun Nam, Seulki Lee, Jae Hyung Park, Rang-Woon Park, In-San Kim, Kuiwon Choi, Sang Yoon Kim, Kinam Park, Ick Chan Kwon, Journal of Controlled Release, 2010, Volume 146, Issue 2, Pages 219–227)

3.  Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA (Hong Yeol Yoon, Sejin Son, So Jin Lee, Dong Gil You, Ji Young Yhee, Jae Hyung Park, Maggie Swierczewska, Seulki Lee, Ick Chan Kwon, Sun Hwa Kim, Kwangmeyung Kim & Martin G. Pomper, Scientific Reports, 2014, 4, Articlenumber:6878)


logo_Bioacts.png

Satisfaction
Quality Rating
Value Rating
Style Rating
X